company background image
SGEN

Seagen NasdaqGS:SGEN Stock Report

Last Price

US$137.72

Market Cap

US$25.4b

7D

-2.7%

1Y

-16.2%

Updated

28 Sep, 2022

Data

Company Financials +
SGEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SGEN Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$137.72
52 Week HighUS$192.79
52 Week LowUS$105.43
Beta0.62
1 Month Change-12.49%
3 Month Change-22.17%
1 Year Change-16.15%
3 Year Change62.91%
5 Year Change136.47%
Change since IPO1,569.33%

Recent News & Updates

Sep 26

Seagen in licensing deal with Lava Therapeutics for cancer candidate

Seagen Inc. (NASDAQ:SGEN) announced a license agreement with Dutch biotech LAVA Therapeutics N.V. (LVTX) on Monday for preclinical candidate LAVA-1223 which is designed to target epidermal growth factor receptor (EGFR)-expressing solid tumors. Per the terms, SGEN will pay $50M upfront to LAVA to receive an exclusive worldwide license for LAVA-1223 which uses the latter's proprietary Gammabody technology. The deal also includes up to about $650M milestone payments and royalties on future sales in the range of single digits to the mid-teens. Additionally, the agreement gives SGEN, which focuses on antibody-drug conjugates for cancer, exclusive rights of negotiation to apply LAVA's Gammabody platform on up to two additional tumor targets. LVTX shares have added ~113% pre-market in reaction to the deal, and SGEN is trading flat. SGEN, which was rumored to have attracted buyout interest from Merck (MRK), lost in value in recent days as M&A prospects cooled.

Sep 14

Seagen ticks lower as management suggests it could look at acquisitions

Seagen (NASDAQ:SGEN) ticked down 0.3% as management appeared to indicate the biotech company would be looking at acquisitions rather than being acquired. Seagen management is currently presenting at the Morgan Stanley 20th Annual Global Healthcare Conference. "I would not be surprised to see Seagen move forward on some pretty creative and accretive corporate development initiatives," a Seagen executive said at the conference. The comments come after a a Bloomberg report late last month that talks with Merck (MRK) to buy the company have stalled for the time being. The talks are said to have ended over a disagreement on price. Developing story ...

Shareholder Returns

SGENUS BiotechsUS Market
7D-2.7%2.9%-2.0%
1Y-16.2%-24.2%-20.3%

Return vs Industry: SGEN exceeded the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: SGEN exceeded the US Market which returned -22.1% over the past year.

Price Volatility

Is SGEN's price volatile compared to industry and market?
SGEN volatility
SGEN Average Weekly Movement4.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: SGEN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: SGEN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,675Roger Danseyhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGEN fundamental statistics
Market CapUS$25.40b
Earnings (TTM)-US$739.80m
Revenue (TTM)US$1.78b

14.3x

P/S Ratio

-34.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGEN income statement (TTM)
RevenueUS$1.78b
Cost of RevenueUS$1.59b
Gross ProfitUS$186.14m
Other ExpensesUS$925.93m
Earnings-US$739.80m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.01
Gross Margin10.47%
Net Profit Margin-41.61%
Debt/Equity Ratio0%

How did SGEN perform over the long term?

See historical performance and comparison